OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 225,000 shares of the biopharmaceutical company's stock, valued at approximately $412,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.86% of Inovio Pharmaceuticals as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Alpine Global Management LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 4th quarter worth about $31,000. Bank of Montreal Can bought a new position in Inovio Pharmaceuticals in the 4th quarter valued at about $43,000. Boothbay Fund Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at approximately $44,000. Barclays PLC grew its holdings in shares of Inovio Pharmaceuticals by 15.0% during the 4th quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 5,111 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Inovio Pharmaceuticals by 118.2% during the 4th quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 21,512 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.
Inovio Pharmaceuticals Price Performance
NASDAQ:INO traded down $0.02 during trading hours on Monday, hitting $2.04. The company had a trading volume of 234,408 shares, compared to its average volume of 591,536. The company has a market capitalization of $74.63 million, a PE ratio of -0.64 and a beta of 1.40. The stock has a 50-day moving average price of $1.80 and a 200 day moving average price of $2.46. Inovio Pharmaceuticals, Inc. has a 52 week low of $1.42 and a 52 week high of $12.33.
Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.23. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.01 million. Analysts anticipate that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on INO shares. StockNews.com downgraded shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. Royal Bank of Canada restated a "sector perform" rating and issued a $5.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. HC Wainwright restated a "neutral" rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. Finally, Oppenheimer dropped their price target on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $9.75.
Read Our Latest Analysis on Inovio Pharmaceuticals
About Inovio Pharmaceuticals
(
Free Report)
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Further Reading
Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
